ERBB2 and breast cancer: For instance, Lin and colleagues developed a nanocarrier based on a liposome–PEG–PEI complex that was conjugated with trastuzumab plus curcumin or doxorubicin, proving that the nanomedicine increased the therapeutic effect compared to trastuzumab alone both in vitro and in vivo, specifically in HER2 BC cell lines [198].